Tim Hopper, MBA Helping Medical Device/Drug Delivery Companies Accelerate Commercialization Timelines | Bringing Napkin Sketches to Life October 2015 < 1 min reading time The boundaries between the traditional drug and medtech realms are gradually eroding, being redrawn, and then eroding again. Blurred Lines: Big Pharma’s On-Again Off-Again Relationship with Medtech | QmedThe boundaries between the traditional drug and medtech realms are gradually eroding, being redrawn, and then eroding again. source: https://www.linkedin.com/groups/78665/78665-6057576999977840643 Marked as spam |
Meet your next client here. Join our medical devices group community.
| |
Private answer Brian K. Buntz Thanks, Marrianne. I learned a lot myself about the relationship between pharma and medtech in my interview with the EG-GILERO folks. Marked as spam | |
Private answer Brian K. Buntz The notion of implantable devices that gradually deliver drugs for, say, 6 months at a time is interesting. Wonder how popular that type of technology will be ultimately? On the one hand, users don't have to take pills every day; on the other, you have to have a new implant put in every 6 months for as long as you are taking the course of medicine. Marked as spam | |
Private answer Edward Dolan Brian and George both make very good points. At an MDG symposium on combination products 2 years ago, Andrew von Eschenbach made the point that the future is building on a basketball model, not a golf model: collaboration across disciplines, not solo heroes. Marked as spam |
Please log in to post questions.